阿帕替尼在晚期非小细胞肺癌姑息治疗中应用的近期效果观察

Short-term curative effect of apatinib in palliative therapy of advanced non-small cell lung cancer

目的探讨阿帕替尼在晚期非小细胞肺癌(NSCLC)姑息治疗中应用的近期疗效。方法抽取安阳市肿瘤医院2019年1月至2020年12月收治的晚期NSCLC患者109例为研究对象,按随机数字表法分为对照组(54例)与观察组(55例)。对照组给予止痛抑吐等最佳支持疗法,观察组在最佳支持疗法基础上加用阿帕替尼治疗,均治疗8周,并进行1年随访。比较两组临床疗效、治疗期间不良反应发生率、治疗前后生存质量中心调查表(QLQ-C30)评分,并比较两组随访1年后的生存率。结果观察组治疗总有效率(7.27%,4/55)、疾病控制率(50.91%,28/55)均高于对照组(0.00%,0/54;20.37%,11/54),P均<0.05。治疗后,两组QLQ-C30各维度评分均高于治疗前,且观察组QLQ-C30各维度评分均高于对照组(P均<0.05)。观察组患者出现不同程度高血压、手足综合征、蛋白尿等不良反应,且主要为Ⅰ~Ⅱ级。观察组1年生存率(74.54%,41/55)高于对照组(55.56%,30/54),P<0.05。结论在晚期NSCLC姑息治疗中应用阿帕替尼的近期疗效较好,可明显提高患者的生活质量和生存率,且药物不良反应轻微。

Objective To investigate the short-term curative effect of apatinib in palliative therapy of advanced non-small cell lung cancer(NSCLC).Methods A total of 109 patients with advanced NSCLC admitted to Anyang Cancer Hospital from January 2019 to December 2020 were enrolled as the research objects.And they were divided into control group(54 cases)and observation group(55 cases)by random number table method.The control group was given the best supportive therapy(relieving pain,emetic suppression),while the observation group was given apatinib palliative therapy based on the treatment of the control group.All of them were treated for 8 weeks,and were followed up for 1 year.The clinical curative effect,incidence of adverse reactions during treatment,scores of quality of life core questionnaire(QLQ-C30)before and after treatment,and survival rate after 1 year of follow-up were compared between the two groups.Results The total response rate and disease control rate in the observation group(7.27%,4/55;50.91%,28/55)were higher than those in the control group(0.00%,0/54;20.37%,11/54),allP<0.05.Scores of every item of QLQ-C30 after treatment were higher than those before treatment in the two groups,and postoperative scores of every item of the observation group were higher than those of the control group(all P<0.05).In the observation group,there were adverse reactions such as hypertension at varying degrees,hand-foot syndrome and proteinuria,which were mainly on gradesⅠ-Ⅱ.The 1-year survival rate in the observation group(74.54%,41/55)was higher than that in the control group(55.56%,30/54),P<0.05.Conclusions Apatinib palliative therapy has good short-term curative effects on patients with advanced NSCLC,which can significantly improve quality of life and survival rate,with mild adverse drug reactions and high safety.